Psoriasis;Psoriasis

Annales de Dermatologie et de Venereologie

Volumn 124, Issue 1, 1997, Pages 91-101

  El Sayed, F ^a   Marguery, M C ^a  

^a CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AURANOFIN; CALCIPOTRIOL; CYCLOSPORIN; CYCLOSPORIN A; FUMARIC ACID; LIAROZOLE; METHOTREXATE; METHOXSALEN; PEPTIDE T; RETINOID; TACROLIMUS; TAZAROTENE; TIOGUANINE; TUMOR NECROSIS FACTOR; ULOBETASOL PROPIONATE; ZIDOVUDINE;

CLINICAL TRIAL; HUMAN; PHOTOTHERAPY; PSORIASIS; PUVA; REVIEW; TREATMENT INDICATION; ULTRAVIOLET B RADIATION;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; CALCITRIOL; DERMATOLOGIC AGENTS; GLUCOCORTICOIDS; HUMANS; PHOTOCHEMOTHERAPY; PSORIASIS; RETINOIDS;

EID: 0031039689     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Greaves MW, Weinstein GD. Treatment of psoriasis. N Enel J Med 1995;332:581-8.
2. Bessis D, Guilhou JJ. Le psoriasis. Actualités sur les traitements locaux. Objectif peau 1995;2:297-301.
3. Guilhou JJ. Stratégie thérapeutique dans le psoriasis. Ann Dermatol Vcnereol 1996;123:276-279.
4. Fredriksson T, Pettersson U. Severe psoriasis - Oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
5. Dubertret L. Psoriasis: la stratégie thérapeutique. Objectif peau 1995;2:305-7.
6. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995;132:236-44.
7. Feldman SR, Fleischer AB, Rapp SR, Reboussin DM, Exum ML, Clark AR. The severity of psoriasis symptoms and signs in a population of psoriasis patients. AAD, 54th Annual meeting, february 10-15, 1996, Washington, Poster 292.
8. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989;95:(suppl) 2-4.
9. Impson KE, Lowe NJ. Trends in topical psoriasis therapy. Int J Dermatol 1994;33:333-336.
10. Liem WH, Mc Cullough JL, Weinstein GD. Effectiveness of topical therapy for psoriasis: results of a national survey. Cutis 1995;55:306-10.
11. David M, Lowe NJ. Psoriasis therapy: Comparative studies with a hydrocolloid dressing, plastic film occlusion and triamcinolone acetonide cream. J Am Acad Dermatol 1989;21:511-14.
12. Van de Kerkof PCM, Ghang A, Van der Walle HB, Van Vlijmen-Willems I, Boezeman JBM, Huigen-Tijdnik R. Weekly treatment of psoriasis with a hydrocolloid dressing in combination with triamcinolone acetonide. A controlled Comparative Study. Acta Derm Venereol (Stock) 1994;74:143-46.
13. Arbiser JL, Grossman K, Kaye E, Arndt KA. Use of short-course class 1 topical glucocorticoid under occlusion for the rapid control of erythodermic psoriasis. Arch Dermatol 1994;130:704-6.
14. Griffiths CEM, Tranfaglia MG, Kang S. Prolonged occlusion in the treatment of psoriasis: a clinical and immunohistologic study. J Am Acad Dermatol 1995;32:618-22.
15. Meola T., Soter NA., Lim HW. Are topical corticosleroids useful adjunctive therapy for the treatment of psoriasis with ultraviolet radiation ? Arch Dermatol 1991;127:1708-1713
16. Higgins EM, Du Vivier A. Glucocorticoïdes. In Dubertret L. ISED, ed du Dôme 1995, 274 p., pp 102-11.
17. Kragballe K, Beck HI, Sogaard H. Improvement of psoriasis by a topical vitamin D3 analogue (MC903) in a double-bind study. Br J Dermatol 1988;119:223-30.
18. Highton A, Quel J and The Calcipotriene Study Group Culcipotriene ointment 0,005 p. 100 for psoriasis: A safety and efficacy study. J Am Acad Dermatol 1995;32:67-72.
19. Berth-Jones J, Chu AC, Dodd WAH, Ganpule M, Griffiths WAD, Haydey RP, et al. A multicentre parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992;127:266-71.
20. Tham SN, Lun KC, Cheong WK. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 1994;131:673-7.
21. Kienbaum S, Lehmann P, Ruzicka Th. Topical calcipotriol in the treatment of intertriginous psoriasis. AAD, 54th Annual meeting, february 10-15, 1996, Washington, Poster 290.
22. Mc Creary HL, Siskin SB, Epinette WW. Calcipotriene 0,005 p. 100 cream in the treatment of patients with plaque psoriasis. AAD, 54th Annual meeting, february 10-15, 1996, Washington, Poster 298.
23. Molin L, Cutler TP, Helander I, Nyfors B. Calcipotriene cream equally effective as betamethasone valerate cream. AAD, 54th Annual meeting, february 10-15. 1996, Washington, Poster 282.
24. Ortonne JP. Psoriasis: nouvelle modalité thérapeutique par le calcipotriol plus le dipropionate de bétaméthasone. Nouv Dermatol 1994;13:746-51.
25. Wilde M, Siskin SB, Epinette WW. A comparison of the safety and efficacy of Calcipotriene ointment 0,005 p. 100, halobetasol propionate 0,05 p. 100, and alternating application of both in the treatment of plaque psoriasis. AAD, 54th Annual meeting, february 10-15, 1996. Washington, Poster 315.
26. Green C, Ganpule M, Harris D, Kavanagh G, Kennedy C, Mallett R, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994;130:483-87.
27. Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: Results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994;31:68-74.
28. Speight EL, Farr PM. Calcipotriol improves the response of psoriasis to PUVA. J Dermatol 1994;130:79-82.
29. Klaher MR, Hutchinson PE, Pedvis-Leftick A, Kraballe K, Reumala TL, Van De Kerkhof PCM et al. Comparative effects of calcipotriol solution (50 μg/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis.Br J Dermatol 1994;131:678-83.
30. Perez A, Chen TC, Turner A, Holick MF. Pilot study of topical calcitriol ( 1,25-Dihydroxyvitamin D3) for treating psoriasis in children. Arch Dermatol 1995;.31:961-62.
31. Kokelj F, Lavaroni G, Perkan V, Plozzer C. Hyperpigmentation due to calcipotriol (MC 903) plus heliotherapy in psoriatic patients. Three case reports. Acta Derm Venereol (Stockh) 1995;75:307-9.
32. Mc Kenna KE, Stern RS. Photosensitivity associated with combined UVB and calcipotriol therapy. Br J Dermatol 1995;133.Suppl. 45:63.
33. Rigopoulos D, Aroni K, Stratigos JT. Generalized pustular psoriasis precipitated by topical calcipotriol cream. Int J Dermatol 1994;33:515-6.
34. Schubert B, Juillard J. Goudrons. In Dubertret L. ISED, ed du Dôme 1995, 274p., pp. 116-22.
35. Lowe NJ, Wortzinan MS, Breeding J, Koudsi H, Taylor L. Coaltar phototherapy for psoriasis reevaluated. Erythemogenic versus sub erythemogenic UV with a tar extract in oil and crude coaltar. J Am Acad Dermatol 1983;8:781-9.
36. Verschoore M, Shroot B. Anthraline. In Dubertret L. ISED, cd du Dôme 1995, 274p., pp. 112-15.
37. Schaefer H, Farber EM, Goldberg L, Schalla W. Limited application period for dithranol in psoriasis: preliminary report on penetration and clinical efficacy. Br J Dermatol 1989;102:571-3.
38. Lowe NJ, Ashton RE, Koudsi H, Verschoore M, Schaefer H. Anthralin for psoriasis: short-contact anthralin therapy compared with topical steroid and conventional anthralin. J Am Acad Dermatol 1984;10:69-72.
39. Zvulunov A, Anisefeld A, Metzker A. Efficacy of short-contact therapy with dithranol in childhood psoriasis. Int J Dermatol 1994;.33:808-810.
40. Berg M, Ros AM. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen. Photodermatol Photoimmunol Photomed 1994;10:217-20.
41. Sakuntabhai A, Diffey BL, Farr PM. Calculation of 8-methoxypsoralen dose according to body surface area in PUVA treatment. Br J Dermatol 1995;133:919-23.
42. Sakuntabhai A, Sharpe GR, Farr PM. Response of psoriasis to twice weekly PUVA. Br J Dermatol 1993;128:166-71.
43. Buckley DA, Healy E, Rogers S. A comparison of twice - weekly skin - PUVA regimens for the treatment of psoriasis. Br J Dermatol 1995;133:417-22.
44. Roetlandts R. Le point sur la PUVAthérapie en 1994. Nouv Dermatol 1994;13:158-70.
45. British Photodermatology Group. British Photodermatology Group Guide lines for PUVA. Br J Dermatol 1994;130:246-55.
46. Castelneau JP. Quand et comment arrêter la PUVAthérapie dans le psoriasis. Ann Dermatol Venereol 1994;121:602-5.
47. Lindelof B, Sigurgeirsson B, Tegner E, Larkö O, Johannesson A, Berne B, et al. PUVA and cancer: a large - scale epidemiological study. Lancet 1991;338:91-3.
48. Studniberg HM, Weller P. PUVA, UVB, psoriasis, and nonmelanoma skin cancer. J Am Acad Dermatol 1993;29:1013-22.
49. Storbeck K, Hölzle E, Schurer N, Lehmann P, Plewig G. Narrow-band UVB (311 nm) versus conventional broad-band UVB with and without dithranol in phototherapy for psoriasis. J Am Acad Dermatol 1993;28:227-31.
50. Picot E, Meunier L, Picot-Debeze MC, Peyron JL, Meynadier J. Treatment of psoriasis with a 311-nm UVB lamp. Br J Dermatol 1992;127:509-12.
51. Sakuntabhai A, Diffey BL, Farr PM. Response of psoriasis to psoralen-UVB photochemotherapy. Br J Dermatol 1993;128:296-300.
52. Lowe NJ, Prytrowsky JH, Bourget T, Edelstein J, Nychay S, Arrmstrong R. Acitretin plus UVB therapy for psoriasis. J Am Acad Dermatol 1991;24:591-4.
53. Iest J, Boer J. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 1989;120:665-70.
54. Gupta AK, Ellis CN, Tellner DC, Anderson TF, Voorhees JJ. Double-blind, placebo-controlled study to evaluate the efficacy of fish oil an low-dose UVB in the treatment of psoriasis. Br J Dermatol 1989;120:801-7.
55. Kristensen B, Kristensen O. Topical salicylic acid interferes with UVB therapy for psoriasis. Acta Derm Venereol (Stockh) 1991;71:37-40.
56. Fotiades J. Lim HW, Jiang SB, Soter NA, Sanchez M, Moy JA. Efficacy of ultraviolet B (UVB) phototherapy for psoriasis in HIV-infected patients. AAD, 54th Annual meeting, february 10-15, 1996, Washington, Poster 299.
57. Lowe N J, Weingarten D, Bourget T, Moy LS. PUVA therapy for psoriasis: comparison of oral and bath-water delivery of 8-methoxypsoralen. J Am Acad Dermatol 1986;14:754-60.
58. Gomez MI, Azana ZM, Arranz I, Harto A, Ledo A. Plasma levels of 8-MOP after bath-PUVA for psoriasis: relationship to disease severity. Br J Dermatol 1995;133:37-40.
59. Gomez MI, Perez B, Harto A, De Misa RF, Ledo A. 8-MOP bath PUVA in the treatment of psoriasis: clinical results in 42 patients. J Dermatol Treat 1996;7:11-2.
60. Streit V, Henseler T, Christophers E. Balneophototherapy - A nationwide study for the treatment of psoriasis in Germany. AAD, 54th Annual meeting, february 10-15, 1996, Washington, Poster 283.
61. David JA, Rose T, Bearman JE. Treatment of psoriasis at a Dead sea dermatology clinic. Int J Dermatol 1995;34:134-7.
62. Pfiester HR, Marquait C, Lipsker D Grosshans E. La photothérapie associée aux bains salés. Ann Dermatol Venereol 1996;123:414-6.
63. Hawk JLM, Le Grice P. The efficacy of localized PUVA therapy for chronic hand and foot dermatoses. Clin Exp Dermatol 1994;19:479-82.
64. Handfield-Jones SE, Boyle J, Harman RRM. Local treatment for nail psoriasis. Br J Dermatol 1987:116:280-1.
65. Berbis P, Geiger JM, Vaisse C, Rognin C, Privat Y. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatologica 1989;178:88-92.
66. Pilkington T, Brogden RN. Acitretin. A review of its pharmacology and therapeutic use. Drugs 1992;43:597-627.
67. Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ. Side effects profile of acitretin therapy in psoriasis. J Am Acad Dermatol 1989;20:1088-93.
68. Stern RS, Fitzgerald E, Ellis CN, Lowe N, Goldfarb MT, Baughman RD. The safety of etretinate as long- term therapy for psoriasis: results of the etretinate follow-up study. J Am Acad Dermatol 1995;33:44-52.
69. Saurat JH, Geiger JM, Amblard P, Beani JC, Boulanger A, Claudy A et al. Randomized double blind multicenter study comparing acitretin-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 1988;177:218-24.
70. El Darouti, Al Rubaie. Psoriasis treatment with RePUVA in the United Arab Emirates. Int J Dermatol 1988;27:593-5.
71. Van Dooren-Greebe RJ, Kuijpers ALA, Mulder J, De Boo Th, Van De Kerkhof PCM. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994;130:204-10.
72. Collins P, Rogers S. The efficacy of methotrexate in psoriasis - a review of 40 cases. Clin Exp Dermatol 1992;17:257-60.
73. Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A.. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995;13:589-93.
74. Mazer JM. Ciclosporine et psoriasis grave. Ann Dermatol Venereol 1996;123:280-4.
75. Ellis CN, Fradin MS, Hamilton TA. Voorhees JJ. Duration of remission during maintenance cyclosporine therapy for psoriasis. Arch Dermatol 1995;131:791-5.
76. Laburte C, Grossman R, Abirached J, Abeywickrama KH, Dubertret L.. Efficacy and safety of oral cyclosporin A (Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994;130:366-75.
77. Mrowietz U, Farber, L, Von Zepelin HHH, Bachmann H, Welzel D, Christophers E. Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study. J Am Acad Dermatol 1995;33:470-5.
78. Wagner S.A, Peter R.U, Adam O, Ruzicka T. Therapeutic efficacy of oral low-dose cyclosporin A in severe psoriatic arthritis. Dermatology 1993;186:62-7.
79. Mahrle G, Schulze HJ, Färber L, Weidinger G, Steigleder GK. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995;32:78-88.
80. Bretchel B, Wellenreuther U, Toppe E, Czarnetzki BM. Combination of etretinate with cyclosporine in the treatment of severe recalcitrant psoriasis. J Am Acad Dermatol 1994;30:1023-4.
81. Helm KF, Marks JG, Leyden JJ, Guzzo C, Krueger GG, Griffiths TW, Griffiths CEM. Topical auranofin ointment for the treatment of plaque psoriasis. J Am Acad Dermatol 1995;33:517-9.
82. Weinstein G, Jeffes E, Duvic M Friedman D, Jegasothy B,Tharp M, et al. Tazarotene gel for the treatment of plaque psoriasis: a double-blind clinical study. AAD, 54th Annual meeting, february 10-15, 1996, Washington, Poster 286.
83. Katugampola G.A, Rees A.M, Larrigan S.W. Laser treatment of psoriasis. Br J Dermatol 1995;135:909-13.
84. Takematsu H, Takahashi K, Tagami H. Systemic tumour necrosis factor (TNF) treatment in psoriasis: clinical data from a total of 14 patients in an open trial. J Dermatol Treat 1994;5:133-7.
85. Marcusson JA, Lazega D, Pert CB, Ruff M, Sundquist KG, Wetterberg L. Peptide T and psoriasis. Acta Derm Venereol (Stockh) 1989;suppl1146:117-21.
86. Farber EM, Cohen EN, Trozak D,J Wilkinson DI. Peptide T improves psoriasis when infused into lesions in nanogram amounts. J Am Acad Dermatol 1991;25:658-64.
87. Johansson O, Hilliges M, Talme T, Marcusson JA, Wetterbereg L. Somatostatin immunoreactive cells in lesional psoriatic human skin during peptide T treatment. Acta Derm Venereol (Stockh) 1994;74:106-9.
88. Zackheim HS, Glogau RG, Fisher DA Maibach HI. 6-Thioguanine treatment of psoriasis: experience in 81 patients. J Am Acad Dermatol 1994;30:452-8
89. Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994;30:977-81.
90. Kristensen JK, Petersen LJ, Hansen U, Nielsen H, Stahl Skov P, Nielsen HJ. Systemic high-dose ranitidine in the treatment of psoriasis: an open prospective clinical trial. Br J Dermatol 1995;133:905-8.
91. Witkamp L, Velthuis PJ, Verhaegh MEJM, Hulsman RFHJ, Bossuyt PMM, Bos JD, Meinardi MMHM. An open prospective clinical trial with systemic ranitidine in the treatment of psoriasis. J Am Acad Dermatol 1993;28:778-81.
92. Wallach D, Cottenot F. Cimetidine versus placebo in the treatment of psoriasis. Dermatologica 1982;165:197-203.
93. Urrea AA, Vélez GM, Nogues AE, Camarasa JG. Psoriasis in an HIV-positive patient treated with cimetidine. Dermatology 1995;191:77.
94. Bourke JF, Berth-Jones J, Holder J, Graham-Brown RAC. A new microemulsion formulation of cyclosporin (Neoral) is effective in the treatment of cyclosporin-resistant dermatoses. Br J Dermatol 1996;134:777-9.
95. Bos JD, Ruzicka T, Rubins A. An European, multicenter, randomized, double-blind study to evaluate the safety and efficacy of FK 506(tacrolimus) in the treatment of severe psoriasis. Skin Pharmacol 1995;8:74.
96. Docks P, Decree J, Degreef H. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: an open study with oral liarozole. Br J Dermatol 1995;133:426-32.
97. Heenen M, Maddin S, Iglesias J, Dubertret L, Davies M, De Doucker P, Heremans A. Oral treatment of severe plaque psoriasis: one open and one double-blind placebo-controlled study. AAD, 54th Annual meeting, february 10-15, 1996, Washington, Poster 312.
98. Duvic M, Crane MM, Conant M, Mahoney SE, Reveille JD, Nusinoff Lehrman S. Zidovudine improves psoriasis in Human immunodeficiency virus-positive males. Arch Dermatol 1994;130:447-51.
99. Townsed BL, Cohen PR, Duvic M. Zidovudine for the treatment of HIV-negative patients with psoriasis. J Am Acad Dermatol 1995;32:994-9.
100. Ghadially R, Halkier-Sorensen L, Elias PM. Effects of petrolatum on stratum corneum structure and function. J Am Acad Dermatol 1992;26:387-96.
101. Ruzika T. Psoriatic arthritis. Arch Dermatol 1996;132:215-9.
102. Bonifazi E, Mazzotta F. Traitement du psoriasis de l'enfant. Ann Dermatol Venereol 1992;119:792-5.
103. Brun P. Psoriasis du cuir chevelu: traitement. In Dubertret L. Psoriasis ISED/eds du Dôme, 1995, pp. 217-9.
104. Gueissaz F, Borradori L, Dubertret L. Psoriasis unguéal. Ann Dermatol Venereol 1992;119:57-63.
105. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993;28:454-9.
106. Menter MA, See JA, Amend WJC, Ellis CN, Krueger GG, Lcbwohl M, et al. Proceedings of the psoriasis combination and rotation therapy conference. J Am Acad Dermatol 1996;.34:315-21.